Dr. Claudia Götzberger-Schad, Bayer HealthCare AG, Wuppertal, Germany

Automation platforms are an integral part along the antibody generation and development process in the Global Biologics organization at Bayer. The presentation will touch on automation in antibody screening and small-scale IgG production and focus on our recent achievements to support the generation of antibody production cell lines. A fully automated platform was implemented for parallelization and streamlining of the cell line development process with the goal to reduce overall project timelines. Parallel handling of up to six clone selection campaigns is achieved through a tailored integration of robotics hardware and advanced software modules.